- Case report
- Open Access
- Open Peer Review
Visceral leishmaniasis due to Leishmania infantumwith renal involvement in HIV-infected patients
- Matteo Vassallo1Email author,
- Olivier Moranne2, 3, 4,
- Damien Ambrosetti5,
- Pierre-Yves Jeandel6,
- Christelle Pomares7,
- Elisabeth Cassuto2,
- Annick Boscagli1,
- Guillaume Giraud1,
- Nathalie Montagne1,
- Chiara Dentone8,
- Ilaria Demacina8,
- Barbara Villaggio9,
- Giovanni Secondo8,
- Giuseppe Ferrea8,
- Corinne Passeron10,
- Laurence Saudes1,
- Regis Kaphan1,
- Pierre Marty7 and
- Eric Rosenthal6
© Vassallo et al.; licensee BioMed Central Ltd. 2014
- Received: 31 March 2014
- Accepted: 14 October 2014
- Published: 30 October 2014
We describe histological, clinical findings and outcomes of renal involvement during Leishmania infantum infection in four HIV-infected patients in South France and North Italy hospital settings.
Four HIV-infected Caucasian patients (age 24-49) performed renal biopsy during episodes of visceral leishmaniasis. They presented severe immunosuppression, frequent relapses of visceral leishmaniasis during a follow-up period of several years and partial or complete recovery of renal function after anti-parasitic treatment. Main clinical presentations were nephrotic or nephritic syndrome and/or acute renal failure secondary to membranoproliferative type III glomerulonephritis or acute interstitial nephritis. Clinical outcome was poor, probably as a consequence of insufficient immuno-virological control of the HIV infection.
Our findings suggest that the main histological findings in case of renal involvement due to Leishmania infantum infection in HIV-infected patients are type III MPGN and acute interstitial nephritis, with a histological specificity similar to that observed in canine leishmaniasis. Poor immune status in HIV-infected patients, altering the capacity for parasite clearance, and prolonged course of chronic active VL in this population may lead to the development of specific renal lesions.
- Visceral Leishmaniasis
- Renal Involvement
- Secondary Prophylaxis
Leishmaniasis due to Leishmania infantum is a vector-borne disease which is endemic in Southern Europe -. In humans, Leishmania infection gives rise to a range of presentations (mainly visceral, cutaneous and mucosal) depending on the species involved and the effectiveness of the patient’s immune response to the parasite ,,. Visceral leishmaniasis (VL) is present in 61 countries across 4 continents where 200 million people are exposed. Approximately 0.2 to 0.4 million cases of VL and 0.7 to 1.2 million cases of cutaneous leishmaniasis occur each year, with 5 countries (India, Nepal, Bangladesh, Sudan, Brazil) accounting for 90% of these, whereas the condition remains sporadic in Southern Europe -. In immunosuppressed individuals, including HIV-infected patients, the clinical presentation of VL can be atypical , easily misdiagnosed or mistaken as a flare-up of the underlying disease. Before the introduction of combination antiretroviral therapy (cART), the incidence of VL was higher in HIV-infected patients than in immunocompetent subjects, with higher rates of relapse and mortality . In the cART era, the incidence of VL in the HIV-infected population has dramatically decreased -. Moreover, with the longer life expectancy of HIV-infected individuals, new clinical features of VL have been reported, such as active chronic VL, characterized by relapses over a period of several years and continuous circulation of the parasite in the bloodstream .
Renal involvement in HIV-infected patients with VL is uncommon and few cases have been reported -. Patients displayed various patterns of clinical and histological presentation: isolated proteinuria or hematuria, nephrotic syndrome (proteinuria >2.5 g/day, hypoalbuminemia and generalized oedema), nephritic syndrome (glomerular proteinuria & hematuria, reduced glomerular filtration rate with varying degrees of azotemia, oliguria and hypertension) secondary to membrano-proliferative glomerulonephritis (MPGN) or amyloidosis, and acute kidney injury (AKI) secondary to interstitial nephritis -.
We present a series of four cases of VL due to Leishmania infantum with renal involvement in HIV-infected patients, including histological findings and clinical outcome. Patients were hospitalized between 1996 and 2012 in Infectious Diseases Hospital departments in the Alpes-Maritimes, France and in Liguria, Italy, where Leishmania infantum infection is endemic.
Case report n° 1
A 40-year-old HIV-infected male patient, born and residing in the Nice area (Alpes-Maritimes, South-Eastern France), was admitted to hospital in June 2011 for persistent diarrhoea and weight loss (5 kgs). He had contracted HIV-infection in 1996, and his previous medical history included VL in 2000, (with clinical relapses in 2005 and 2009 but no renal involvement), high blood pressure, cerebral toxoplasmosis and Kaposi’s sarcoma in 2003, and pneumocystis pneumonia in 2006. His antiretroviral regimen included etravirine, darunavir and ritonavir. The latest CD4 cell count was 114 cells/mm3 (nadir: 46 cells/mm3) and HIV viral load was 162 copies/ml. Compliance with cART had frequently been sub-optimal. He presented with nephritic syndrome, urine dipstick analysis revealing proteinuria and hematuria, but no leukocyturia. Blood pressure was 150/100 mmHg, with peripheral œdema. All kidney tissue samples were obtained via needle biopsy. Light microscopy examination showed diffuse hyper-cellularity with thickening of the glomerular basement membrane, and immunofluorescence microscopy revealed IgG, IgM, C3 and C1q mesangial and endo-membranous deposits . According to the World Health Organisation (WHO) classification, the histological findings were typical of type III membrano-proliferative glomerulonephritis (MPGN).
Diagnosis of VL was based on molecular methods using Leishmania infantum polymerase chain reaction (PCR) (Taqman technology; Light Cycler target: kinetoplast mini-circle DNA) on peripheral blood and other biological samples, i.e. bone marrow, urine and kidney . In this patient, qualitative PCR was positive in both urine and peripheral blood. VL relapse was suspected and liposomal Amphotericine B (l-Ampho-B), 3 mg/kg daily, initially scheduled for 10 days, was prematurely discontinued due to deteriorating renal function and suspected drug-associated tubulopathy. The patient’s condition gradually improved and secondary VL prophylaxis consisting in monthly intravenous pentamidine infusions was initiated. During follow-up, creatinine levels remained stable and viro-immunological parameters improved. The patient was re-admitted in October 2013 for another relapse of VL. Poor cART compliance was suspected. The CD4 T-cell count and plasma HIV-RNA level were 79 cells/mm3 and 1,500 copies/ml, respectively. PCR was positive for Leishmania infantum with 992 parasites/ml in plasma and 322 parasites/106 cells in bone marrow. Treatment with l-Ampho-B was started, adapting dosage to renal function; fever resolved, parasitemia dropped to 312 parasites/ml and the estimated glomerular filtration rate (eGFR) remained stable. Antiretroviral treatment was switched from a twice-daily to a once-daily regimen, in order to improve compliance. The patient was discharged and continued secondary VL prophylaxis as an outpatient with L-Ampho-B.
Description of cases of VL with renal injury and outcome
Years since HIV contamination
Years since diagnosis of visceral Leishmaniosis
Leishmania quantitative PCR test (parasites/ml)
C4 concentration (normal range 0.14-0.33 g/l)
Positive type 2
HCV viral load in blood (qualitative)
Serum albumin (g/l) at time of diagnosis or during follow-up
Platelets >150000 giga/L at time of renal biopsy
HIV viral load (copies/ml)
CD4 T-cell count (cells/mm 3 )
CD4 T-cell nadir (cells/mm 3 )
Plasma creatinine concentrations (year, [μmol/l]) diagnosis/follow-up
2006 (100)/2007 (265)/2008(488)
154 / 99
55 / 60
CKD-EPI (ml/min/1.73 m 2 ) diagnosis/follow-up
105 / 90 / 52
Daily proteinuria (g/day) Diagnosis/follow-up
0.3 / 0.5
2.0 / 0.5
Kidney histological findings
MPGN III and Interstitial nephropathy
MPGN III and interstitial nephropathy
Treatment and outcome
VL treatment regimen
Improved but worsened at clinical relapse
Description of kidney histo-pathological diagnosis
MPGN type III
MPGN type III
Acute interstitial nephritis
MPGN type III
Diffuse hypercellularity and thickening of glomerular basement membrane.
Subendothelial and subepithelial deposits with mesangial interposition associated with basement membrane spikes
Acute interstitial nephritis: edema associated with interstitial lymphoplasmocytic infiltration in addition to mild tubulointerstitial fibrosis.
Subendothelial and subepithelial deposits and mesangial interposition associated with basement membrane spikes.
Free Leishmania in a capillary lumen
Tubules are invaded by lymphocytes and areas of necrosis are visualized.
Interstitial granuloma. Positive PCR for Leishmania infantum in urine and in renal biopsy
Positive PCR for Leishmania infantum in the renal biopsy
Glomeruli are uninvolved. Free Leishmania in a capillary lumen
Mesangial and endomembranous deposits of IgG, IgM, C3 and C1q
Fine granular deposition of IgG and C3 in the mesangium and along the peripheral capillary loops
Deposits of IgG and IgM with a mesangial pattern
Mesangial and endomembranous deposits of IgG and C3
Case report n° 2
A 35-year-old male patient, HIV-infected since 1997, born and residing in the Nice area (Alpes-Maritimes, South-Eastern France), was first admitted to hospital in 1998 with VL. He was treated with l-Ampho-B and symptoms improved. During the following years, the patient had several relapses of VL despite various secondary prophylaxis regimens, including l-ampho-B, pentamidine and miltefosine. In 2004 he was re-admitted with suspected clinical relapse of VL. His CD4 cell count was 20 cells/mm3 while HIV viral load exceeded 100,000 copies/ml. Leishmania infantum parasites were found both in colon biopsy samples and in peripheral blood. Moreover, liver biopsy showed large macrophages containing Leishmania infantum. An additional course of l-Ampho-B resulted in clinical recovery and was followed by maintenance therapy. The eGFR was normal. Compliance with cART was poor and the CD4 T-cell count remained below 200 cells/mm3.
In 2006 the patient presented with nephrotic syndrome. C4 and C3 concentrations were normal, while HIV viral load and CD4 T-cell count were 41,000 copies/ml and 12 cells/mm3, respectively. Leishmania amastigotes were observed on a blood smear. A renewed course of l-ampho-B resulted in remission of the nephrotic syndrome.
Compliance with antiretroviral treatment remained poor and in 2008 the patient was admitted to hospital for the fourth time due to renewed relapse with diarrhœa, weight loss and œdema. His HIV-RNA and CD4 T-cell count were 74,000 copies/ml and 200 cells/mm3, respectively. The patient died due to renal failure despite anti-parasitic treatment with l-Ampho-B.
Case report n° 3
A 24 year-old female patient, born in Italy and a resident of the Sanremo area (Liguria, North-Western Italy), HIV-infected via maternal-fœtal transmission, was admitted to hospital in 2012 for weight loss and AKI.
Treatment with l-Ampho-B was started and resulted in improved eGFR. Antiretroviral treatment was modified according to genotyping results. The patient was discharged and secondary prophylaxis with l-Ampho-B was continued. A recent outpatient follow-up visit showed stable renal function, normal urinary sediment microscopy and proteinuria of 0.53 g/24 hrs. Despite the persistent clinical relapse-free period, PCR remained positive on blood (736 parasites/ml) with a CD4 T-cell count below 200 cells/mm3 while the HIV viral load did not exceed50 copies/ml.
Case report n° 4
A 49-year-old male patient, born and residing in the Nice area (Alpes-Maritimes, South-Eastern France), HIV and hepatitis C (HCV) co-infected since the age of 16, was admitted to hospital in 2011 for weight loss, œdema and nephrotic syndrome without hematuria. The eGFR was normal. VL had been previously diagnosed in 1991 and treated, resulting in symptom resolution.
Laboratory tests upon admission showed undetectable HCV and HIV viral loads, and a CD4 T-cell count of 84 cells/mm3. The antiretroviral regimen included abacavir, lamivudine and lopinavir/ritonavir.
We describe four cases of VL due to Leishmania infantum in HIV-infected patients in the cART era, with specific PCR or microscopic proof of renal involvement.
All patients had severe immunosuppression, and had presented with recurring episodes of clinical relapse of VL over a follow-up period of several years. Moreover, they had partial or complete recovery of renal function after anti-parasitic treatment associated with better control of HIV infection. The main clinical presentations included nephrotic or nephritic syndrome secondary to type III MPGN or acute kidney injury secondary to interstitial nephritis.
According to the WHO classification, based on ultrastructural alterations in the glomerular basement membrane, MPGN is subdivided into 3 categories: type I (sub-endothelial deposits), type II (intra-membranous dense deposits) and type III, where deposits are found in the sub-endothelial and mesangial region, similarly to type I, but, in addition, with numerous sub-epithelial deposits . Histological findings reported in our series are in line with sporadic cases described in humans and in studies on dogs, where type III MPGN was the most commonpattern -,,. Interestingly, free Leishmania were observed inside the capillary lumen of two patients.
MPGN during VL is probably the result of immune complex deposition occurring during chronic infection ,,. However, other mechanisms of injury have been suggested in dogs: indeed, there is growing evidence that T-cell migration into the glomeruli and adhesion molecules play a fundamental role in the pathogenesis of certain immunologically-mediated cases of glomerulonephritis . Costa et al. found considerably higher numbers of CD4 T-cells in dogs with VL compared to uninfected animals, with no relevant associated immune complex deposition. The number of T-cells was correlated to the quantity of Leishmania antigen in phagocytic cells, suggesting that the parasite itself could directly drive the inflammatory infiltrate in the glomeruli. Enhanced expression of adhesion molecules, such as P-selectin and ICAM-1, has also been found in the mesangium and glomerular capillaries of animals and humans with VL, thus suggesting that newly migrated platelets could play a role in the pathogenesis of renal injury. Finally, diminished apoptosis may be another possible mechanism contributing to the persistence and progression of glomerular hyper-cellularity .
Acute interstitial nephritis was the other presentation of renal involvement secondary to Leishmania infantum infection reported in this series. This is probably the result of parasitic dissemination, as reported by other authors in a human kidney transplant recipient  and in dogs ,. Tubular necrosis could be secondary to ischemia due to small vessel obliteration by Leishmania spp., while haemolysis and necrotizing tubulitis could be a consequence of parasitic invasion and inflammatory response ,.
The correlation between immunosuppression and clinical relapse of VL has been suggested by Bourgeois et al., who showed that the persistence of CD4 T-cell counts <100 cells/mm3 is one of the main risk factors for relapse . Since the advent of cART, features of HIV/Leishmania spp. coinfection include a chronic course of parasitic disease with latent parasitemia and a high rate of relapse. Bourgeois et al. defined the condition as “active chronic VL”, where patients have long-term persistence of circulating Leishmania species with alternating symptomatic and asymptomatic phases. As showed by Kubar et al. , patients with relapsing VL generally have lower CD4 T-cell counts than HIV-infected patients with primary VL, suggesting that in addition to the T-cell-mediated response, essential at the time of primary Leishmania infection, supplementary mechanisms might operate in case of chronic infection.
Patients described in this series received various antiparasitic agents including l-Ampho-B, pentamidine and miltefosine. They all responded, at least partially, but they sufferedseveral relapses despite secondary prophylaxis. Data regarding secondary prophylaxis of VL in HIV-infected patients are scarce, explaining the absence of guidelines favouring a particular regimen . There is no consensus on the management of active chronic VL. It is currently suggested that parasite detection by PCR, together with CD4 T-cell count, may guide decisions for prolonging or stopping prophylaxis in HIV-infected patients -. Bourgeois et al. suggest that secondary prophylaxis could be discontinued in patients taking cART when either 1) PCR remains negative for at least 6 months and CD4 T-cell count is >200 cells/mm3 or 2) CD4 T-cell count is <200 cells/mm3 but PCR remains negative for at least 18 months .
This case series showed that the clinical outcome of VL and renal injury is associated with viro-immunological control of HIV infection, suggesting that immune restoration plays a pivotal role in preventing relapse. In this case series, suboptimal compliance with antiretroviral treatment was probably the main cause of poor immune recovery, as proven by frequent episodes of viral replication during follow-up. However, VL itself might play a role: Leishmania co-infection could enhance viral replication and immune activation, thus contributing to CD4 T-cell depletion and increasing the risk of reactivation of latent infections ,. Thus, even patients with successful antiretroviral treatment could be at risk for Leishmania re-activation.
Finally, in this series, patients presented with active chronic VL progressing over a protracted course, ranging from 2 to 19 years (median 8 yrs). In mixed cryoglobulinemia due to hepatitis C virus, another condition mediated by immune complex deposition, vasculitis-related symptoms, including renal involvement, are associated with longer duration of HCV infection . Similarly, in active chronic VL, prolonged infection may be required to develop renal disease.
Our results suggest that the main histological findings in case of renal involvement due to Leishmania infantum infection in HIV-infected patients are type III MPGN and acute interstitial nephritis, with specific histological features similar to those observed in canine leishmaniasis. Poor immune status in HIV-infected patients, altering the capacity for parasite clearance, and prolonged course of chronic active VL in this population may lead to the development of these specific renal lesions. These patients should thus be regularly screened for Leishmania infantum infection and their renal function closely monitored.
Written informed consent was obtained from patients for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
We thank all patients for accepting to participate in the collection of data.
We also wish to thank Julie Medway for paper revision.
- Berman JD: Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997, 24 (Suppl 4): 684-703. 10.1093/clind/24.4.684.View ArticlePubMedGoogle Scholar
- Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, Molina R, Moreno J: Leishmania and human immunodeficiency virus co-infection: the first 10 years. J Clin Microbiol Rev. 1997, 10: 298-319.Google Scholar
- Oliveira CMC, Oliveira MLMB, Andrade SCA, Girao CS, Ponte CN, Mota MU, Fernandes PFCBC, Campos HH, Esmeraldo RM, Evangelista JB: Visceral leishmaniasis in renal transplant recipients: clinical aspects, diagnostic problems, and response to treatment. Transplant Proc. 2008, 40 (Suppl 3): 755-760. 10.1016/j.transproceed.2008.02.039.View ArticlePubMedGoogle Scholar
- Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, Den Boer M: Leishmaniasis worldwide and global estimates of its incidence. Plos One. 2012, 7 (suppl. 5): e35671-10.1371/journal.pone.0035671.View ArticlePubMedPubMed CentralGoogle Scholar
- Pérez-Molina JA, López V, Guerrero A: Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals. Am J Med. 1997, 102 (Suppl 1): 132-PubMedGoogle Scholar
- Herwaldt BL: Leishmaniasis. Lancet. 1999, 354: 1191-1199. 10.1016/S0140-6736(98)10178-2.View ArticlePubMedGoogle Scholar
- Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J: The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008, 21 (Suppl 2): 334-359. 10.1128/CMR.00061-07.View ArticlePubMedPubMed CentralGoogle Scholar
- Rosenthal E, Marty P, Poizot M, Reynes J, Platlong F, Lafeuillade A, Jaubert D, Boulat O, Dereure G, Gamabarelli A: Visceral leishmaniasis and HIV-1 co-infection in Southern France. Trans R Soc Trop Med Hyg. 1995, 89: 159-162. 10.1016/0035-9203(95)90476-X.View ArticlePubMedGoogle Scholar
- Rosenthal E, Tempesta S, Del Giudice P, Marty P, Desjeux P, Pradier C, Le Fichoux Y, Cassuto JP: Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS. 2001, 15: 1884-1885. 10.1097/00002030-200106150-00017.View ArticleGoogle Scholar
- Rybniker J, Goede V, Mertens J, Ortmann M, Kulas W, Kochanek M, Benzing T, Arribas JR, Fatkenheuer G: Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure-a case report and brief review of the literature. Int J Infect Dis. 2010, 14: 522-525. 10.1016/j.ijid.2009.06.010.View ArticleGoogle Scholar
- Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M: Spread of vector-borne diseases and neglect of Leishmaniasis. Europe Emerg Infect Dis. 2008, 14 (Suppl 7): 1013-1018. 10.3201/eid1407.071589.View ArticlePubMedGoogle Scholar
- Rosenthal E, Marty P: Leishmaniose viscérale. Rev Prat. 2004, 54 (Suppl 20): 2211-2216.PubMedGoogle Scholar
- Del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E: Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a french cohort of patients infected with human immunodeficiency virus. J Infect Dis. 2002, 186: 1366-1370. 10.1086/344325.View ArticlePubMedGoogle Scholar
- Bourgeois N, Bastien P, Reynes J, Makinson A, Rounet I, Lachaud L: Active chronic visceral leishmaniasis” in HIV-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med. 2010, 11 (Suppl 10): 670-673. 10.1111/j.1468-1293.2010.00846.x.View ArticlePubMedGoogle Scholar
- Amann K, Bogdan C, Harrer T, Rech J: Renal leishmaniasis as unusual cause of nephrotic syndrome in an HIV patient. J Am Soc Nephrol. 2012, 23: 586-590. 10.1681/ASN.2011050472.View ArticlePubMedPubMed CentralGoogle Scholar
- Davidson RN: Practical guide for the treatment of leishmaniasis. Drugs. 1998, 56: 1009-1018. 10.2165/00003495-199856060-00005.View ArticlePubMedGoogle Scholar
- Suankrantay C, Suwanpimolkul G, Wilde H, Siriyasatien P: Case report: Autochtonus visceral leishmaniasis in a human immunodeficiency virus (HIV)-infected patient: the first in Thailand and review of the literature. Am J Trop Med Hyg. 2010, 82 (Suppl 1): 4-8. 10.4269/ajtmh.2010.09-0434.View ArticleGoogle Scholar
- Jarvis JN, Lockwood DN: Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis. 2013, 26: 1-9. 10.1097/QCO.0b013e32835c2198.View ArticlePubMedGoogle Scholar
- Dettwiler S, McKee T, Hadaya K, Chappuis F, van Deiden C, Moll S: Visceral Leishmaniasis in a kidney transplant recipient: parasitic interstitial nephritis, a cause of renal dysfunction. Am J Transplant. 2010, 10: 1486-1489. 10.1111/j.1600-6143.2010.03125.x.View ArticlePubMedGoogle Scholar
- Alex S, Criado C, Fernandez-Guerrero ML, de Gorgolas M, Petkov V, Garcia Perez A, Egido J, Barat A, Manzarbeitia F, Carmelo C, Ortiz A: Nephrotic syndrome complicating chronic visceral leishmaniasis: re-emergence in patients with AIDS. Clin Nephrol. 2008, 70 (Suppl 1): 65-68.PubMedGoogle Scholar
- Clevenbergh P, Nkoumou Okome M, Benoit S, Bendini JC, De Salvador F, Elbeze M, Cassuto E, Marty P, Dellamonica P: Acute renal failure as initial presentation of visceral leishmaniasis in an HIV-1 infected patient. Scand J Infect Dis. 2002, 34 (Suppl 7): 546-547. 10.1080/003655402320208857.View ArticlePubMedGoogle Scholar
- Daher EF, Rocha NA, Oliveira MJ, Franco LF, Oliveira JL, Silva Junior GB, Abreu KL, Henn GA, Martins AM, Libório AB: Renal function improvement with pentavalent antimonial agents in patients with visceral leishmaniasis. Am J Nephrol. 2011, 33 (Suppl 4): 332-336. 10.1159/000324914.View ArticlePubMedGoogle Scholar
- Mary C, Faraut F, Lascombe L, Dumon H: Quantification of Leishmania infantum DNA by a real-time PCR assay with sensitivity. J Clin Microbiol. 2004, 42: 5249-5255. 10.1128/JCM.42.11.5249-5255.2004.View ArticlePubMedPubMed CentralGoogle Scholar
- Aresu L, Valenza F, Ferroglio E, Pregel P, Uslenghi F, Tarducci A, Zanatta R: Membranoproliferative glomerulonephritis type III in a simultaneous infection of Leishmania infantum and Dirofilaria immitis in a dog. J Vet Diagn Invest. 2007, 19 (Suppl 5): 569-572. 10.1177/104063870701900520.View ArticlePubMedGoogle Scholar
- Rollino C, Bellis D, Beltrame G, Basolo B, Montemagno A, Bucolo S, Ferro M, Quattrocchio G, Coverlizza S, Quarello F: Acute renal failure in leishmaniasis. Nephrol Dial Transplant. 2003, 18: 1950-1951. 10.1093/ndt/gfg267.View ArticlePubMedGoogle Scholar
- Poli A, Abramo F, Mancianti F, Nigro M, Pieri S, Bionda A: Renal involvement in canine leishmaniasis: a light-microscopic, immunohistochemical and electron-microscopic study. Nephron. 1991, 57: 444-452. 10.1159/000186348.View ArticlePubMedGoogle Scholar
- Costa FAL, Prianti MG, Silva TC, Silva SMMS, Guerra JL, Goto H: T cells, adhesion molecules and modulation of apoptosis in visceral leishmaniasis glomerulonephritis. BMC Infect Dis. 2010, 10: 112-10.1186/1471-2334-10-112.View ArticlePubMedPubMed CentralGoogle Scholar
- Clerici M, Hakim FTD, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM: Changes in interleukine 2 and interleukine 4 in asymptomatic human immunodeficiency virus seropositive individuals. J Clin Invest. 1993, 91: 759-765. 10.1172/JCI116294.View ArticlePubMedPubMed CentralGoogle Scholar
- D’Ettorre G, Ceccarelli G, Carnevalini M, Forcina G, Zaffiri L, Massetti AP, Mastroianni CM, Vullo V: Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Trop. 2006, 99: 83-87. 10.1016/j.actatropica.2006.08.002.View ArticlePubMedGoogle Scholar
- Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P: Long-term monitoring of visceral leishmaniasis in patients who have AIDS. J Acquir Immune Defic Syndr. 2008, 48 (Suppl 1): 13-19. 10.1097/QAI.0b013e318166af5d.View ArticlePubMedGoogle Scholar
- Kubar J, Marty P, Lelièvre A, Quaranta JF, Staccini P, Caroli-Bosc C, Le Fichoux Y: Visceral leishmaniasis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocytes counts. AIDS. 1998, 12: 2147-2153. 10.1097/00002030-199816000-00009.View ArticlePubMedGoogle Scholar
- Buffet PA, Rosenthal E, Gangneux JP, Lightburne E, Couppié P, Morizot G, Lachaud L, Marty P, Dedet JP: Therapy of leishmaniasis in France: consensus on proposed guidelines. Presse Med. 2011, 40 (Suppl. 2): 173-184. 10.1016/j.lpm.2010.09.023.View ArticlePubMedGoogle Scholar
- Pintado V, Lopez-Velez L: Visceral leishmaniasis associated with human immunodeficiency virus infection. Enferm Infecc Microbiol Clin. 2001, 19: 353-357. 10.1016/S0213-005X(01)72665-1.View ArticlePubMedGoogle Scholar
- Cota GF, de Sousa MR, Demarqui FN, Rabello A: The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012, 6 (5): e1665-10.1371/journal.pntd.0001665.View ArticlePubMedPubMed CentralGoogle Scholar
- Mary C, Faraut F, Drogoul MP, Xeridat B, Schleinitz N, Cuisenier B, Dumon H: Reference values for Leishmania infantum parasitemia in different clinical presentations: quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up. Am J Trop Med Hyg. 2006, 75 (Suppl 5): 858-863.PubMedGoogle Scholar
- Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Uberti-Foppa C, Cinque P: Real-time assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol. 2003, 41: 5080-5084. 10.1128/JCM.41.11.5080-5084.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Okwor I, Uzonna JE: The immunology of Leishmania/HIV coinfection. Immunol Res. 2013, 56: 163-171. 10.1007/s12026-013-8389-8.View ArticlePubMedGoogle Scholar
- Andreani G, Lodge R, Richard D, Tremblay MG: Mechanisms of interaction between protozoan parasites and HIV. Curr Opin HIV AIDS. 2012, 7: 276-282. 10.1097/COH.0b013e32835211e9.View ArticlePubMedGoogle Scholar
- Sene D, Ghillani-Dalbin P, Thibault V, Guis L, Musset L, Duhaut P, Poynard T, Piette JC, Cacoub P: Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol. 2004, 31: 2199-2206.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.